参考文献/References:
[1] Ryu KW, Kim DS, Kraus WL.New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose)polymerases[J].Chem Rev,2015,115(6):2453-2481.
[/br][2] Gibson BA, Kraus WL.New insights into the molecular and cellular functions of poly(ADP-ribose)and PARPs[J].Nat Rev Mol Cell Biol,2012,13(7):411-424.
[/br][3] Bai P, Nagy L, Fodor T,et al.Poly(ADP-ribose)polymerases as modulators of mitochondrial activity[J].Trends Endocrinol Metab,2015,26(2):75-83.
[/br][4] Shevalye H, Maksimchyk Y, Watcho P,et al.Poly(ADP-ribose)polymerase-1(PARP-1)gene deficiency alleviates diabetic kidney disease[J].Biochim Biophys Acta,2010,802(11):1020-1027.
[/br][5] Narne P, Ponnaluri KC, Siraj M,et al.Polymorphisms in oxidative stress pathway genes and risk of diabetic nephropathy in South Indian type 2 diabetic patients[J].Nephrology(Carlton),2014,19(10):623-629.
[/br][6] Drel VR, Xu W, Zhang J, et al. Poly(Adenosine 5'-diphosphate-ribose)polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy[J].Endocrinology,2009,150(2):5273-5283.
[/br][7] Shevalye H, Stavniichuk R, Xu W,et al.Poly(ADP-ribose)polymerase(PARP)inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model[J].Biochem Pharmacol,2010,79(7):1007-1014.
[/br][8] Toth-Manikowski S, Atta MG.Diabetic kidney disease: pathophysiology and therapeutic targets[J].J Diabetes Res,2015,2015:697010.
[/br][9] Czapski GA, Adamczyk A, Strosznajder RP,et al.Expression and activity of PARP family members in the hippocampus during systemic inflammation: their role in the regulation of prooxidative genes[J].Neurochem Int,2013,62(5):664-673.
[/br][10] Du X, Matsumura T, Edelstein D,et al.Inhibition of GAPDH activity by poly(ADP-ribose)polymerase activates three major pathways of hyperglycemic damage in endothelial cells[J].J Clin Invest, 2003,112(7):1049-1057.
[/br][11] Nakajima H, Kubo T, Ihara H,et al.Nuclear-translocated glyceraldehyde-3-phosphate dehydrogenase promotes poly(ADP-ribose)polymerase-1 activation during oxidative/nitrosative stress in stroke[J].J Biol Chem,2015,290(23):14493-14503.
[/br][12] Kassan M, Choi SK, Galán M,et al.Enhanced NF-kB activity impairs vascular function through PARP-1-,SP-1-, and COX-2- dependent mechanisms in type 2 diabetes[J].Diabetes, 2013,62(6):2078-2087.
[/br][13] Qin WD, Wei SJ, Wang XP,et al.Poly(ADP-ribose)polymerase 1 inhibition protects against low shear stress induced inflammation[J].Biochim Biophys Acta,2013,1833(1):59-68.
[/br][14] Sun Y, Zhou L, Lv D,et al.Poly(ADP-ribose)polymerase 1 inhibition prevents interleukin-1β-induced inflammation in human osteoarthritic chondrocytes[J].Acta Biochim Biophys Sin(Shanghai), 2015,47(6):422-430.
[/br][15] Hasegawa K, Wakino S, Simic P,et al.Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes [J].Nat Med,2013,19(11):1496-1504.
[/br][16] Papadimitriou A, Silva KC, Peixoto EB,et al.Theobromine increases NAD+/Sirt-1 activity and protects the kidney under diabetic conditions[J]Am J Physiol Renal Physiol,2015,308(3):F209-F225.
[/br][17] Wang S,Yang X,Lin Y,et al.Cellular NAD depletion and decline of SIRT1 activity play critical roles in PARP-1-mediated acute epileptic neuronal death in vitro[J].Brain Res,2013,1535:14-23.
[/br][18] Zerfaoui M, Errami Y, Naura AS, et al.Poly(ADP-ribose)polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-k B upon TLR4 stimulation[J]. J Immunol,2010,185(3):1894-1902.
[/br][19] Qin WD, Mi SH, Li C, et al.Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation response [J].PLoS One,2015,10(3):e0120586.
[/br][20] Xu B, Chiu J, Feng B,et al. PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes[J].Diabetes Metab Res Rev,2008,24(5):404-412.
[/br][21] Kim BK,Im JY,Han G,et al.p300 cooperates with c-Jun and PARP-1 at the p300 binding site to activate RhoB transcription in NSC126188-mediated apoptosis[J].Biochim Biophys Acta,2014,839(5):364-373.
[/br][22] Minchenko AG,Stevens MJ,White L,et al.Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose)polymerase activation[J].FASEB J,2003,17(11):1514-1516.
[/br][23] Chiu J, Xu BY, Chen S,et al.Oxidative stress-induced,poly(ADP-ribose)polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications[J]. Can J Physiol Pharmacol,2008,86(6):365-372.
[/br][24] Magorzewicz S, Skrzypczak-Jankun E, Jankun J.Plasminogen activator inhibitor-1 in kidney pathology(Review)[J].Int J Mol Med,2013,31(3):503-510.
[/br][25] Zhu H,Jiang Z, Lei P, et al.Poly(ADP-ribose)polymerase-1 mediates angiotensin Ⅱ-induced expression of plasminogen activator inhibitor-1 and fibronectin in rat mesangial cells[J].Kidney Blood Press Res,2011,34(5):320-327.
[/br][26] Coleman RL, Sill MW, Bell-McGuinn K,et al.A phase Ⅱ evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study[J].Gynecol Oncol,2015,137(3):386-391.
[/br][27] Kapoor K, Singla E, Sahu B,et al.PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice[J].Mol Cell Biochem,2015,400(1-2):153-162.
相似文献/References:
[1]李雅,王志斌,刘玮晔,等.巨噬细胞与糖尿病肾病[J].国际内分泌代谢杂志,2014,(06):393.[doi:10.3760/cma.j.issn.1673-4157.2014.06.009]
Li Ya*,Wang Zhibin,Liu Weiye,et al.Macrophages and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(06):393.[doi:10.3760/cma.j.issn.1673-4157.2014.06.009]
[2]王丹,关美萍,薛耀明.早期生长反应因子-1与糖尿病肾病[J].国际内分泌代谢杂志,2014,(06):397.[doi:10.3760/cma.j.issn.1673-4157.2014.06.010]
Wang Dan,Guan Meiping,Xue Yaoming..Early growth response factor-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(06):397.[doi:10.3760/cma.j.issn.1673-4157.2014.06.010]
[3]翟丽敏,叶山东.二甲双胍的抗炎作用及其糖尿病肾脏保护作用[J].国际内分泌代谢杂志,2014,(05):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
Zhai Limin,Ye Shandong..Anti-inflammatory effects of metformin and its renal protection in diabetes[J].International Journal of Endocrinology and Metabolism,2014,(06):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
[4]玄先法,李清芹,王玉新,等.肾炎康复片联合缬沙坦治疗Ⅳ期糖尿病肾病蛋白尿的临床研究[J].国际内分泌代谢杂志,2014,(05):353.[doi:10.3760/cma.j.issn.1673-4157.2014.05.019]
Xuan Xianfa,Li Qingqin,Wang Yuxin,et al.Clinical study of Shenyankangfu tablet combined with valsartan capsule on proteinuria in patients with stage Ⅳ diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(06):353.[doi:10.3760/cma.j.issn.1673-4157.2014.05.019]
[5]曹萌 陈堃 茅晓东 刘超.限食治疗糖尿病肾病的研究进展[J].国际内分泌代谢杂志,2015,(06):395.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.009]
Cao Meng,Chen Kun,Mao Xiaodong,et al.Effects of diet restriction on diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(06):395.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.009]
[6]马静茹,牟新.表观遗传学与糖尿病肾病[J].国际内分泌代谢杂志,2016,36(01):52.[doi:10.3760/cma.j.issn.1673-4157.2016.01.013]
Ma Jingru*,Mou Xin..Epigenetics and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):52.[doi:10.3760/cma.j.issn.1673-4157.2016.01.013]
[7]杨薇,李春君,孙蓓,等.雷公藤多苷对糖尿病肾病大鼠核因子-κB
信号通路的影响[J].国际内分泌代谢杂志,2016,36(02):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
Yang Wei*,Li Chunjun,Sun Bei,et al.Effects of triperygium wilfordii polyglucoside on nuclear factor-κB signaling pathway in rats with diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
[8]刘艳,田秀标,韩颖,等.血管紧张素1-7与糖尿病及糖尿病肾脏
内质网应激关系的研究[J].国际内分泌代谢杂志,2016,36(03):157.[doi:10.3760/cma.j.issn.1673-4157.2016.03.04]
Liu Yan*,Tian Xiubiao,Han Ying,et al.Relationship between angiotensin 1-7, diabetes and endoplasmic reticulum stress of diabetic kidney[J].International Journal of Endocrinology and Metabolism,2016,36(06):157.[doi:10.3760/cma.j.issn.1673-4157.2016.03.04]
[9]周宇,柯甦捷,刘礼斌.血尿酸与糖尿病肾病[J].国际内分泌代谢杂志,2016,36(03):202.[doi:10.3760/cma.j.issn.1673-4157.2016.03.15]
Zhou Yu,Ke Sujie,Liu Libin..Serum uric acid and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):202.[doi:10.3760/cma.j.issn.1673-4157.2016.03.15]
[10]李爱琴,林立平,王钧,等.尿脂联素与糖尿病肾病严重程度的
相关性研究[J].国际内分泌代谢杂志,2016,36(04):233.[doi:10.3760/cma.j.issn.1673-4157.2016.04.06]
Li Aiqin,Lin Liping,Wang Jun,et al.Relationship between urinary adiponectin and the severity of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):233.[doi:10.3760/cma.j.issn.1673-4157.2016.04.06]